【Insights】PD-1/VEGF: Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

2025-07-10

【Insights】CD276 Heats Up: The Race for the Next Blockbuster ADC

2025-07-17

【Insights】CLDN18.2×4-1BB：I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

2025-07-18

【Insights】OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer

2025-07-24

【Insights】IL-23 in the Spotlight: Tremfya® Advances in Crohn’s Disease

2025-07-25

【Insights】GLP1R：Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

2025-07-31

【Insights】Securing Market Share in the IL-17 Era: First Movers vs Fast Followers

2025-08-01

【Insights】GLP-1R/GCGR/GIPR：Novo Nordisk Delivers Strong H1 2025 Results, Driven by Soaring GLP-1 Drug Sales

2025-08-07

【Insights】DLL3 Target Trend Surges: A Rising Star in Small Cell Lung Cancer Therapy

2025-09-03

【Insights】Rise of PD-1/VEGF/CTLA-4 Triple Antibodies: Immunotherapy 2.0 and Its Accelerated Development

2025-09-05

【Insights】TSLP: The Emerging Key Target in Autoimmune Diseases

2025-09-05

【Insights】OX40L:Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study

2025-09-05

【Insights】The Multifaceted Role of Claudin-1: Regulation of Cancer, Inflammation, and Fibrosis with Therapeutic Implications

2025-09-10

【Insights】2025 WCLC Witnesses: EGFR-Mutant NSCLC Enters the EGFR×HER3 Dual-Target Combination Era

2025-09-17

【Insights】FGF21: The Next Breakthrough in Metabolic Drugs?

2025-09-24

【Insights】GLP-1R: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

2025-09-28

【Insights】FGFR: The Next Breakthrough Target in Cancer Treatment

2025-10-15

【Insights】CDH17:Roche’s $1.45 Billion Licensing Deal with Hansoh Pharma Spotlights CDH17 ADC Innovation

2025-10-17

【Insights】TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy

2025-10-23

【Insights】PD-1 × IL-2: A Combined Approach to Redefining Tumor Immunotherapy Strategies

2025-10-31